1 / 39

PRODUCTION

PRODUCTION. Design of New HIV-Protease Inhibitors and Ritonavir Synthesis . BY. Sathaporn Prutipanlai. Toxicology Program. Mahidol University. OUT LINE. Background Content : Processes of Ritonavir Synthesis : Possibility for synthesis new PIs Conclusion. BACKGROUND.

jenn
Télécharger la présentation

PRODUCTION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PRODUCTION

  2. Design of New HIV-Protease Inhibitors and Ritonavir Synthesis

  3. BY Sathaporn Prutipanlai Toxicology Program Mahidol University

  4. OUT LINE • Background • Content • : Processes of Ritonavir Synthesis • : Possibility for synthesis new PIs • Conclusion

  5. BACKGROUND • What is characteristic of HIV Protease enzyme.? • HIVProtease is one type of aspartic acid enzyme.

  6. Protease enzyme • Protease’s function exists as a C2- symmetric homodimer. • Each monomeric unit contributes one of the conserved catalytic triads(Asp-Thr-gly)

  7. HIV Protease Enzyme

  8. BACKGROUND (Cont) • How does it work.? • HIV Protease works by homodimer that cleave gag/pol polypeptide

  9. HIV Protease inhibitor development • Idea : How are enzyme and substrate interact.? • Construct more potent and novel structure of enzyme

  10. Protease enzyme

  11. Inhibitors represent all three categories • Based on peptide isosteres • : statin • Exploitation the symmetrical properties of the protease dimer. • Based on enzyme structure.

  12. Type of Designing Protease Inhibitor • Non hydrolyzable analog of peptide substrates. • Transition-state analogs. • Pepstatin-Protease Complex. • Two-fold symmetrical or Pseudo symmetrical inhibitor. • Structure-Based inhibitor Design

  13. Ritonavir Development • Peptidomimetic inhibitor • Substrate based inhibitor • C2 symmetry-based inhibitor

  14. Ritonavir Development • Design of C2-symmetric inhibitor from an asymmetric substrate compose of 3 steps • First: Imposition an axis of symmetry on the peptide functionality in the substrate

  15. Ritonavir Development(cont) • Second: Arbitary deletion of either the N-terminal or C-terminal. • Third: C2 symmetry operation is applied to the remaining portion to generate a symmetric core unit.

  16. C2-symmetric inhibitor to HIV protease enzyme Imposition of C2-symmetry axes on an asymmetric substrate or inhibitor Kempf, D.J. et.al. 1993

  17. C2 Symmetric HIV PIs Kempf, D.J. et.al 1993

  18. Synthesis of Symmetric Inhibitor Core Units • Three general categories. • : Linear, nonsymmetric syntheses • : Symmetric combination of identical halves • : Bifunctionalization of a C2 symmetric precursor

  19. Linear, Nonsymmetric syntheses Kempf,D.J.1994

  20. Synthesis of Symmetric Inhibitor Core Units(cont) • Three general categories. • : Symmetric combination of identical halves • : Bifunctionalization of a C2 symmetric precursor

  21. Effect of C2-symmetric inhibitors to HIV protease

  22. Processes of Ritonavir Synthesis

  23. Scheme 1 vcl3 + Zn a-aminoaldehyde 2-5-bis-N-((benzyl)oxy)carbonyl)amino-3, 4-diacydroxy-1, 6 diphenylhexane (diols) Patent#5,846,987

  24. Scheme 2 bromoacetate 2-5-bis-N-((benzyl)oxy)carbonyl)amino-3, 4-diacydroxy-1, 6 diphenylhexane Cyclization Hydrolysis Reduction 2,5-Bis-(N(((benzyl)oxyl)carbonyl amino)-3-4-epoxy-1,6 diphenylhaxane 2-5-bis-N-((benzyl)oxy)carbonyl)amino)1, 6 diphenyl-3-hydroxyhexane Patent#5,846,987

  25. Scheme 2 (cont) hydrolysis 2-5-bis-N-((benzyl)oxy)carbonyl)amino)1, 6 diphenyl-3-hydroxyhexane 2, 5, -diamino-1, 6diphenyl-3-hydroxyhexane Patent#5,846,987

  26. Scheme 3 6(1-Amino-2-phenyl)-4-benzyl-2-phenyl-3-aza-2-boro-1-oxacyclohexane 2,5,-Diamino-1,6-diphenyl-3-hydroxyhexane acylation 5-(Thiazolyl)methyl)-(4-nitrophenyl)carbamate 5-Amino-2-(N-((5-thiazolyl)methoxy carbonyl)amino)-1,6-diphenyl-3-hydroxyhexane Patent#5,846,987

  27. Scheme 3 (cont) 5-Amino-2-(N-((5-thiazolyl)methoxy carbonyl)amino)-1,6-diphenyl-3-hydroxyhexane Coupling reaction N-((N-methyl-N-((2-isopropyl-4-thiazoyl methyl)amino)carbonyl-L-valine Ritonavir Patent#5,846,987

  28. Molecular structure of Ritonavir

  29. Ritonavir and protease enzyme

  30. Indinavir and Protease Enzyme

  31. Ritonavir Indinavir Saquinavir Nelfinavir

  32. Possibility to design new protease inhibitor • Factor • : Hydrophobic • : High oral bioavilability • : Low hepatic clearance • : Low toxicity

  33. CONCLUSION • Factor that influence drug design • : Pharmacokinetic • : Pharmacodynamic • : Interaction between inhibitors and HIV- protease enzyme

  34. THANK YOU Dr. Maria Kartalou Dr. Suwit Dr. Poonsak CRI’s Staff YOUR ATTENTION

  35. THE END

More Related